[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NZ193730A - 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions - Google Patents

2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions

Info

Publication number
NZ193730A
NZ193730A NZ193730A NZ19373080A NZ193730A NZ 193730 A NZ193730 A NZ 193730A NZ 193730 A NZ193730 A NZ 193730A NZ 19373080 A NZ19373080 A NZ 19373080A NZ 193730 A NZ193730 A NZ 193730A
Authority
NZ
New Zealand
Prior art keywords
cycloalkenes
diaza
pharmaceutical compositions
pyrimidinyl amino
pyrimidinyl
Prior art date
Application number
NZ193730A
Inventor
A Marxer
K Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NZ193730A publication Critical patent/NZ193730A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ193730A 1979-05-18 1980-05-15 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions NZ193730A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
NZ193730A true NZ193730A (en) 1982-12-21

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ193730A NZ193730A (en) 1979-05-18 1980-05-15 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions

Country Status (21)

Country Link
EP (1) EP0019811A1 (en)
JP (1) JPS55154971A (en)
KR (1) KR830002757A (en)
AR (1) AR228256A1 (en)
AU (1) AU5848480A (en)
DD (1) DD150609A5 (en)
DK (1) DK214480A (en)
ES (1) ES491514A0 (en)
FI (1) FI801600A (en)
GB (1) GB2052487B (en)
GR (1) GR68453B (en)
IE (1) IE49803B1 (en)
IL (1) IL60086A (en)
MA (1) MA18829A1 (en)
NO (1) NO801469L (en)
NZ (1) NZ193730A (en)
OA (1) OA06533A (en)
PL (1) PL224313A1 (en)
PT (1) PT71251A (en)
ZA (1) ZA802909B (en)
ZW (1) ZW11880A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (en) * 1988-08-31 1990-03-01 Bayer Ag METHOD FOR THE PRODUCTION OF SUBSTITUTED N-AZINYL-N'-SULFONYL-ISOTHIO-UREAS AND N-AZINYL-IMINODITHIOCARBONIC ACID-S, S-DIESTER AS INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
CA2269971A1 (en) * 1997-09-03 1999-03-11 Trent Lee Abraham Pyrimidine derivatives
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2266258T3 (en) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated PIRAZOL COMPOUNDS USED AS PROTEIN KINASES INHIBITORS.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002234047A1 (en) 2000-12-21 2002-07-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PL369270A1 (en) * 2001-01-31 2005-04-18 H.Lundbeck A/S Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CN1646500A (en) 2002-03-13 2005-07-27 欧洲凯尔特股份有限公司 Aryl substituted pyrimidines and the use thereof
EP1484971B1 (en) * 2002-03-15 2007-07-04 Ciba SC Holding AG Use of 4-aminopyrimidines for the antimicrobial treatment of surfaces
ATE468336T1 (en) 2002-03-15 2010-06-15 Vertex Pharma AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
KR20050032105A (en) 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Pyrazole compositions useful as inhibitors of gsk-3
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
EP1917259B1 (en) 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
NZ606259A (en) 2005-11-03 2014-06-27 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
EP2086965B1 (en) 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
JP2010513567A (en) 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as inhibitors of protein kinases
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2680029A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579446A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011810A (en) 2007-05-02 2010-01-14 Vertex Pharma Thiazoles and pyrazoles useful as kinase inhibitors.
MX2009011812A (en) 2007-05-02 2010-01-14 Vertex Pharma Aminopyrimidines useful as kinase inhibitors.
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2323622A1 (en) 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CA2745295C (en) * 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
KR102328682B1 (en) * 2018-08-27 2021-11-18 주식회사 대웅제약 Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (en) * 1969-08-14 1971-02-15 Beecham Group Ltd IMINAZOLINES

Also Published As

Publication number Publication date
PL224313A1 (en) 1981-02-13
FI801600A (en) 1980-11-19
ZA802909B (en) 1981-05-27
IE801023L (en) 1980-11-18
AU5848480A (en) 1980-11-20
IL60086A (en) 1984-03-30
KR830002757A (en) 1983-05-30
EP0019811A1 (en) 1980-12-10
MA18829A1 (en) 1980-12-31
JPS55154971A (en) 1980-12-02
DK214480A (en) 1980-11-19
GB2052487A (en) 1981-01-28
PT71251A (en) 1980-06-01
IL60086A0 (en) 1980-07-31
NO801469L (en) 1980-11-19
GB2052487B (en) 1983-05-11
OA06533A (en) 1981-07-31
IE49803B1 (en) 1985-12-25
GR68453B (en) 1981-12-30
DD150609A5 (en) 1981-09-09
AR228256A1 (en) 1983-02-15
ES8104279A1 (en) 1981-04-16
ZW11880A1 (en) 1980-12-17
ES491514A0 (en) 1981-04-16

Similar Documents

Publication Publication Date Title
NZ193730A (en) 2-(pyrimidinyl amino)-1 3-diaza -2- cycloalkenes pharmaceutical compositions
GB2053681B (en) Sustained release pharmaceutical composition
IL58279A0 (en) Sustained release pharmaceutical compositions
GB2053682B (en) Sustained release pharmaceutical compositions
IL60555A0 (en) Pharmaceutical compositions containing certain ureal derivatives
NZ195568A (en) Guanidine derivatives and pharmaceutical compositions
NZ192615A (en) Substituted phenyl j-substituted piperidinoalkanone derivatives and pharmaceutical compositions
AU535604B2 (en) Pharmaceutical compositions
NZ194421A (en) 3-amino-sydnone-imines pharmaceutical compositions
DE3072103D1 (en) Pharmaceutical compositions containing 3-amino-pyrazoline derivatives
PH16443A (en) Substituted tetraazetricyclic compounds and their pharmaceutical compositions
GB2063874B (en) Triazole derivatives processes for the preparation thereof and pharmaceutical compositions containing them
IL70034A0 (en) Heterocyclic amino compounds,their preparation and pharmaceutical compositions containing them
IL60731A0 (en) Pharmaceutical compositions comprising propranolol
GB2056969B (en) 2 - (amino or imino) - 4 - halothiazoles
AU6238680A (en) Pharmaceutical compositions
GB2048671B (en) Pharmaceutical composition containing dihydroegotoxine
GB2050833B (en) Pharmaceutical compositions and process for the preparation thereof
NZ193268A (en) 2-(pyrid-2-yl)-tetrahydrothiophene derivatives and pharmaceutical compositions
IL60813A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
ZA806383B (en) Long acting pharmaceutical composition
PH16220A (en) Pyrro-lidine derivatives and pharmaceutical compositions thereof
IL62809A (en) Antidiarrhoeal pharmaceutical compositions comprising guanidine derivatives
NZ193533A (en) 2-isopropylamino-5-halogeno-pyrimidines pharmaceutical compositions
IL60600A (en) Pharmaceutical compositions comprising certain azolylalkenol compounds